Ionis Pharmaceuticals to present data from Phase 3 on olezarsen

Ionis Pharmaceuticals announced that it will present positive Phase 3 Balance results in patients with familial chylomicronemia syndrome for the company’s lead independent, investigational medicine, olezarsen, at the 2024 American College of Cardiology Annual Meeting in Atlanta, Georgia. The oral presentation will take place on April 7, 2024 at 10:08am ET during the session on Prevention and Health Promotion and the Year in Review. Ionis previously announced positive topline results. As previously shared, monthly dosing of olezarsen 80 mg met the primary endpoint with a statistically significant reduction in triglyceride levels at six months, demonstrated robust reductions in apolipoprotein C-III and marked reductions in acute pancreatitis events versus placebo. Olezarsen also demonstrated a favorable safety and tolerability profile.